jwh 018 profile

1-pentyl-3-(1-naphthoyl)indole: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	10382701
CHEMBL ID	561013
CHEBI ID	185787
SCHEMBL ID	1707018
MeSH ID	M0550481

Synonym
naphthalen-1-yl-(1-pentylindol-3-yl)methanone
1-pentyl-3-(1-naphthoyl)indole
209414-07-3
CHEMBL561013 ,
jwh-018
AKOS005145577
jwh 018
CHEBI:185787
naphthalen-1-yl(1-pentyl-1h-indol-3-yl)methanone
A4549
1-pentyl-3-(1-naphthoyl)-indole
am 678
hsdb 7998
1-pentyl-3-(1-naphthoyl) indole
am-678
g391998j57 ,
dea no. 7118
unii-g391998j57
jwh018
bdbm50353747
j770.893i ,
methanone, 1-naphthalenyl(1-pentyl-1h-indol-3-yl)-
CCG-208715
SCHEMBL1707018
(1-pentyl-1h-indol-3-yl)-1-naphthalenylmethanone
Q-200132
naphthaten-1-yl-(1-pentylindol-3-yl)methanone
DS-3151
gtpl9706
DTXSID10175117
jwh-018 ((naphthalen-1-yl)(1-pentylindol-3-yl)methanone) 1.0 mg/ml in acetonitrile
jwh-018 ((naphthalen-1-yl)(1-pentylindol-3-yl)methanone)
1-naphthalenyl(1-pentyl-1h-indol-3-yl)methanone; am 678; am-678; jwh-018; n-pentyl-3-(1-naphthoyl)indole
jwh-018 ((naphthalen-1-yl)(1-pentylindol-3-yl)methanone) 0.1 mg/ml in acetonitrile
NCGC00386566-01
Q419020
1-pentyl-3-1-naphthoyl-indole
BCP27424
jwh-018,1-ii>>u-3-(1-ya(1/4)xo pound>>u)ssassa
doi:10.14272/jdnlpkcaxicmbw-uhfffaoysa-n.1
10.14272/JDNLPKCAXICMBW-UHFFFAOYSA-N.1
jwh-018, 0.1mg/ml in methanol
jwh-018, 1mg/ml in methanol

Excerpt	Reference	Relevance
" The potential for toxicity exists for users mistakenly associating the dose and side effect profiles of synthetic cannabinoids to those of marijuana."	( Severe toxicity following synthetic cannabinoid ingestion. Hoffman, RS; James, LP; Lapoint, J; Moran, CL; Moran, JH; Nelson, LS, 2011)	0.37

Excerpt	Reference	Relevance
" This study aimed to investigate and compare in vitro and in vivo pharmacodynamic activity of JWH-175 with that of 1-naphthalenyl (1-pentyl-1H-indol-3-yl)-methanone (JWH-018), as well as evaluate the in vitro (human liver microsomes) and in vivo (urine and plasma of CD-1 male mice) metabolic profile of JWH-175."	( In Vivo Bio-Activation of JWH-175 to JWH-018: Pharmacodynamic and Pharmacokinetic Studies in Mice. Arfè, R; Barbieri, M; Bilel, S; Borea, PA; Botrè, F; Camuto, C; Corli, G; De-Giorgio, F; Fantinati, A; Gaudio, RM; Marchetti, B; Marti, M; Mazzarino, M; Tirri, M; Varani, K; Vincenzi, F, 2022)	0.72

Excerpt	Reference	Relevance
" Because SCBs are frequently used in combinations, we hypothesized that coadministering multiple SCBs induces synergistic drug-drug interactions."	( Differential drug-drug interactions of the synthetic Cannabinoids JWH-018 and JWH-073: implications for drug abuse liability and pain therapy. Brents, LK; Fantegrossi, WE; Prather, PL; Saffell, AR; Zimmerman, SM, 2013)	0.39

Excerpt	Reference	Relevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."	( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019)	0.51

Excerpt	Relevance	Reference
"A cumulative dosing THC discrimination procedure was utilized to evaluate sex differences in the discriminative stimulus effects of THC and three synthetic cannabinoids: CP47,497, WIN55,212-2, and JWH-018."	( Comparison of the discriminative stimulus and response rate effects of Craft, RM; Lefever, TW; Marusich, JA; Wiley, JL, 2017)	0.46
" JWH-018, 2 and 3 mg, was administered to six healthy cannabis-experienced volunteers in a placebo-controlled, cross-over study following an escalating dosing schedule."	( Neurocognition and subjective experience following acute doses of the synthetic cannabinoid JWH-018: a phase 1, placebo-controlled, pilot study. de Sousa Fernandes Perna, EB; Hutten, NRPW; Kuypers, KPC; Mason, NL; Ramaekers, JG; Theunissen, EL; Toennes, SW, 2018)	0.48
"JWH-018 dosing in the present study resulted in drug concentrations that were generally low and not fully representative of common use."	( Neurocognition and subjective experience following acute doses of the synthetic cannabinoid JWH-018: a phase 1, placebo-controlled, pilot study. de Sousa Fernandes Perna, EB; Hutten, NRPW; Kuypers, KPC; Mason, NL; Ramaekers, JG; Theunissen, EL; Toennes, SW, 2018)	0.48
" The formation of the metabolite JWH-018 pentanoic acid was found to be slightly delayed, but its rather high concentrations and detection over several weeks after single dosing makes it a useful target for urine analysis."	( Excretion of metabolites of the synthetic cannabinoid JWH-018 in urine after controlled inhalation. Geraths, A; Paulke, A; Pogoda, W; Ramaekers, JG; Theunissen, EL; Toennes, SW; Wunder, C, 2018)	0.48
" Drug deliveries calculated as percent vehicle followed a prototypical inverted-U shaped dose-response curve for cannabinoids and heroin except for THC and JWH-018 (in males)."	( Self-administration of inhaled delta-9-tetrahydrocannabinol and synthetic cannabinoids in non-human primates. Cooper, ZD; Evans, SM; Foltin, RW, 2021)	0.62

Class	Description
indolecarboxamide
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
G	Vesicular stomatitis virus	Potency	1.5092	0.0123	8.9648	39.8107	AID1645842
Interferon beta	Homo sapiens (human)	Potency	1.5092	0.0033	9.1582	39.8107	AID1645842
HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)	Potency	1.5092	0.0123	8.9648	39.8107	AID1645842
Inositol hexakisphosphate kinase 1	Homo sapiens (human)	Potency	1.5092	0.0123	8.9648	39.8107	AID1645842
cytochrome P450 2C9, partial	Homo sapiens (human)	Potency	1.5092	0.0123	8.9648	39.8107	AID1645842
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Fatty acid-binding protein, liver	Mus musculus (house mouse)	Ki	0.0580	0.0210	0.3483	2.0000	AID1802031
Cannabinoid receptor 1	Homo sapiens (human)	Ki	0.0050	0.0001	0.5077	9.6000	AID1127518; AID1632070; AID1767029; AID1853934; AID620178
Cannabinoid receptor 2	Homo sapiens (human)	Ki	0.0057	0.0000	0.4156	10.0000	AID1127517; AID1767030; AID1853935; AID419195; AID620177
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Cannabinoid receptor 1	Homo sapiens (human)	EC50 (µMol)	0.0224	0.0001	0.1275	2.2400	AID1853936; AID1853940; AID620180
Cannabinoid receptor 2	Homo sapiens (human)	EC50 (µMol)	0.0127	0.0003	0.1517	3.2800	AID1853937; AID1853941; AID620181
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
cell surface receptor signaling pathway via JAK-STAT	Interferon beta	Homo sapiens (human)
response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
B cell activation involved in immune response	Interferon beta	Homo sapiens (human)
cell surface receptor signaling pathway	Interferon beta	Homo sapiens (human)
cell surface receptor signaling pathway via JAK-STAT	Interferon beta	Homo sapiens (human)
response to virus	Interferon beta	Homo sapiens (human)
positive regulation of autophagy	Interferon beta	Homo sapiens (human)
cytokine-mediated signaling pathway	Interferon beta	Homo sapiens (human)
natural killer cell activation	Interferon beta	Homo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT protein	Interferon beta	Homo sapiens (human)
cellular response to interferon-beta	Interferon beta	Homo sapiens (human)
B cell proliferation	Interferon beta	Homo sapiens (human)
negative regulation of viral genome replication	Interferon beta	Homo sapiens (human)
innate immune response	Interferon beta	Homo sapiens (human)
positive regulation of innate immune response	Interferon beta	Homo sapiens (human)
regulation of MHC class I biosynthetic process	Interferon beta	Homo sapiens (human)
negative regulation of T cell differentiation	Interferon beta	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Interferon beta	Homo sapiens (human)
defense response to virus	Interferon beta	Homo sapiens (human)
type I interferon-mediated signaling pathway	Interferon beta	Homo sapiens (human)
neuron cellular homeostasis	Interferon beta	Homo sapiens (human)
cellular response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
cellular response to virus	Interferon beta	Homo sapiens (human)
negative regulation of Lewy body formation	Interferon beta	Homo sapiens (human)
negative regulation of T-helper 2 cell cytokine production	Interferon beta	Homo sapiens (human)
positive regulation of apoptotic signaling pathway	Interferon beta	Homo sapiens (human)
response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
B cell differentiation	Interferon beta	Homo sapiens (human)
natural killer cell activation involved in immune response	Interferon beta	Homo sapiens (human)
adaptive immune response	Interferon beta	Homo sapiens (human)
T cell activation involved in immune response	Interferon beta	Homo sapiens (human)
humoral immune response	Interferon beta	Homo sapiens (human)
positive regulation of T cell mediated cytotoxicity	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
adaptive immune response	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independent	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
regulation of T cell anergy	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
defense response	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
immune response	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
detection of bacterium	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
regulation of interleukin-12 production	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
regulation of interleukin-6 production	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
protection from natural killer cell mediated cytotoxicity	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
innate immune response	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
regulation of dendritic cell differentiation	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class Ib	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
positive regulation of acute inflammatory response to antigenic stimulus	Cannabinoid receptor 1	Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger	Cannabinoid receptor 1	Homo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathway	Cannabinoid receptor 1	Homo sapiens (human)
spermatogenesis	Cannabinoid receptor 1	Homo sapiens (human)
axonal fasciculation	Cannabinoid receptor 1	Homo sapiens (human)
response to nutrient	Cannabinoid receptor 1	Homo sapiens (human)
memory	Cannabinoid receptor 1	Homo sapiens (human)
positive regulation of neuron projection development	Cannabinoid receptor 1	Homo sapiens (human)
negative regulation of serotonin secretion	Cannabinoid receptor 1	Homo sapiens (human)
positive regulation of fever generation	Cannabinoid receptor 1	Homo sapiens (human)
negative regulation of fatty acid beta-oxidation	Cannabinoid receptor 1	Homo sapiens (human)
regulation of synaptic transmission, GABAergic	Cannabinoid receptor 1	Homo sapiens (human)
response to lipopolysaccharide	Cannabinoid receptor 1	Homo sapiens (human)
negative regulation of mast cell activation	Cannabinoid receptor 1	Homo sapiens (human)
negative regulation of dopamine secretion	Cannabinoid receptor 1	Homo sapiens (human)
response to nicotine	Cannabinoid receptor 1	Homo sapiens (human)
cannabinoid signaling pathway	Cannabinoid receptor 1	Homo sapiens (human)
response to cocaine	Cannabinoid receptor 1	Homo sapiens (human)
glucose homeostasis	Cannabinoid receptor 1	Homo sapiens (human)
positive regulation of apoptotic process	Cannabinoid receptor 1	Homo sapiens (human)
response to ethanol	Cannabinoid receptor 1	Homo sapiens (human)
negative regulation of action potential	Cannabinoid receptor 1	Homo sapiens (human)
negative regulation of blood pressure	Cannabinoid receptor 1	Homo sapiens (human)
positive regulation of blood pressure	Cannabinoid receptor 1	Homo sapiens (human)
regulation of insulin secretion	Cannabinoid receptor 1	Homo sapiens (human)
regulation of synaptic transmission, glutamatergic	Cannabinoid receptor 1	Homo sapiens (human)
maternal process involved in female pregnancy	Cannabinoid receptor 1	Homo sapiens (human)
regulation of feeding behavior	Cannabinoid receptor 1	Homo sapiens (human)
regulation of penile erection	Cannabinoid receptor 1	Homo sapiens (human)
retrograde trans-synaptic signaling by endocannabinoid	Cannabinoid receptor 1	Homo sapiens (human)
regulation of presynaptic cytosolic calcium ion concentration	Cannabinoid receptor 1	Homo sapiens (human)
trans-synaptic signaling by endocannabinoid, modulating synaptic transmission	Cannabinoid receptor 1	Homo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathway	Cannabinoid receptor 1	Homo sapiens (human)
regulation of metabolic process	Cannabinoid receptor 1	Homo sapiens (human)
response to amphetamine	Cannabinoid receptor 2	Homo sapiens (human)
inflammatory response	Cannabinoid receptor 2	Homo sapiens (human)
immune response	Cannabinoid receptor 2	Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger	Cannabinoid receptor 2	Homo sapiens (human)
leukocyte chemotaxis	Cannabinoid receptor 2	Homo sapiens (human)
negative regulation of synaptic transmission, GABAergic	Cannabinoid receptor 2	Homo sapiens (human)
response to lipopolysaccharide	Cannabinoid receptor 2	Homo sapiens (human)
negative regulation of mast cell activation	Cannabinoid receptor 2	Homo sapiens (human)
cannabinoid signaling pathway	Cannabinoid receptor 2	Homo sapiens (human)
negative regulation of action potential	Cannabinoid receptor 2	Homo sapiens (human)
regulation of metabolic process	Cannabinoid receptor 2	Homo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathway	Cannabinoid receptor 2	Homo sapiens (human)
inositol phosphate metabolic process	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
phosphatidylinositol phosphate biosynthetic process	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
negative regulation of cold-induced thermogenesis	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol phosphate biosynthetic process	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
cytokine activity	Interferon beta	Homo sapiens (human)
cytokine receptor binding	Interferon beta	Homo sapiens (human)
type I interferon receptor binding	Interferon beta	Homo sapiens (human)
protein binding	Interferon beta	Homo sapiens (human)
chloramphenicol O-acetyltransferase activity	Interferon beta	Homo sapiens (human)
TAP binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
signaling receptor binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
protein binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
peptide antigen binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
TAP binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
protein-folding chaperone binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
cannabinoid receptor activity	Cannabinoid receptor 1	Homo sapiens (human)
protein binding	Cannabinoid receptor 1	Homo sapiens (human)
identical protein binding	Cannabinoid receptor 1	Homo sapiens (human)
G protein-coupled receptor activity	Cannabinoid receptor 1	Homo sapiens (human)
protein binding	Cannabinoid receptor 2	Homo sapiens (human)
cannabinoid receptor activity	Cannabinoid receptor 2	Homo sapiens (human)
inositol-1,3,4,5,6-pentakisphosphate kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol hexakisphosphate kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol heptakisphosphate kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol hexakisphosphate 5-kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
protein binding	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
ATP binding	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol hexakisphosphate 1-kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol hexakisphosphate 3-kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol 5-diphosphate pentakisphosphate 5-kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol diphosphate tetrakisphosphate kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
extracellular space	Interferon beta	Homo sapiens (human)
extracellular region	Interferon beta	Homo sapiens (human)
Golgi membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
endoplasmic reticulum	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
Golgi apparatus	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
plasma membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
cell surface	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
ER to Golgi transport vesicle membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
secretory granule membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
phagocytic vesicle membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
early endosome membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
recycling endosome membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
extracellular exosome	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
lumenal side of endoplasmic reticulum membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
MHC class I protein complex	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
extracellular space	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
external side of plasma membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
mitochondrial outer membrane	Cannabinoid receptor 1	Homo sapiens (human)
plasma membrane	Cannabinoid receptor 1	Homo sapiens (human)
actin cytoskeleton	Cannabinoid receptor 1	Homo sapiens (human)
growth cone	Cannabinoid receptor 1	Homo sapiens (human)
presynaptic membrane	Cannabinoid receptor 1	Homo sapiens (human)
membrane raft	Cannabinoid receptor 1	Homo sapiens (human)
glutamatergic synapse	Cannabinoid receptor 1	Homo sapiens (human)
GABA-ergic synapse	Cannabinoid receptor 1	Homo sapiens (human)
plasma membrane	Cannabinoid receptor 1	Homo sapiens (human)
cytoplasm	Cannabinoid receptor 1	Homo sapiens (human)
plasma membrane	Cannabinoid receptor 2	Homo sapiens (human)
dendrite	Cannabinoid receptor 2	Homo sapiens (human)
extrinsic component of cytoplasmic side of plasma membrane	Cannabinoid receptor 2	Homo sapiens (human)
perikaryon	Cannabinoid receptor 2	Homo sapiens (human)
endoplasmic reticulum	Cannabinoid receptor 2	Homo sapiens (human)
plasma membrane	Cannabinoid receptor 2	Homo sapiens (human)
cytoplasm	Cannabinoid receptor 2	Homo sapiens (human)
fibrillar center	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
nucleoplasm	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
cytosol	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
nucleus	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
cytoplasm	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (78)

Assay ID	Title	Year	Journal	Article
AID1346987	P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1296008	Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening	2020	SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1	Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347159	Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346986	P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347160	Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1802031	FABP1 Fluorescent Ligand Displacement Assay from Article 10.1021/acs.biochem.6b00446: \\FABP1: A Novel Hepatic Endocannabinoid and Cannabinoid Binding Protein.\\	2016	Biochemistry, 09-20, Volume: 55, Issue:37	FABP1: A Novel Hepatic Endocannabinoid and Cannabinoid Binding Protein.
AID419196	Selectivity ratio of pKi for CB1 receptor in rat brain to pKi for human cloned CB2 receptor	2009	European journal of medicinal chemistry, Jun, Volume: 44, Issue:6	Development of CoMFA and CoMSIA models of affinity and selectivity for indole ligands of cannabinoid CB1 and CB2 receptors.
AID620184	Thermodynamic solubility of the compound in phosphate buffer at pH 4 after 24 hrs by HPLC analysis	2011	European journal of medicinal chemistry, Oct, Volume: 46, Issue:10	Novel indole and azaindole (pyrrolopyridine) cannabinoid (CB) receptor agonists: design, synthesis, structure-activity relationships, physicochemical properties and biological activity.
AID1211535	Drug metabolism in human liver microsomes assessed as (5-hydroxy-1-pentyl-1H-indol-3-yl)(naphthalen-1-yl)methanone formation at 10 uM after 20 mins by LC-MS/MS analysis	2012	Drug metabolism and disposition: the biological fate of chemicals, Nov, Volume: 40, Issue:11	Cytochrome P450-mediated oxidative metabolism of abused synthetic cannabinoids found in K2/Spice: identification of novel cannabinoid receptor ligands.
AID1562908	Displacement of [3H]HS-665 from KOR in guinea pig brain membranes after 60 mins by liquid scintillation analysis	2019	European journal of medicinal chemistry, Sep-15, Volume: 178	Preparation of bivalent agonists for targeting the mu opioid and cannabinoid receptors.
AID1767029	Displacement of [3H]-CP55940 from human CB1 receptor expressed in CHO cells incubated for 90 mins by liquid scintillation spectrophotometry relative to control	2021	Journal of medicinal chemistry, 05-13, Volume: 64, Issue:9	Synthesis, Molecular Pharmacology, and Structure-Activity Relationships of 3-(Indanoyl)indoles as Selective Cannabinoid Type 2 Receptor Antagonists.
AID1767030	Displacement of [3H]-CP55940 from human CB2 receptor expressed in CHO cells incubated for 90 mins by liquid scintillation spectrophotometry relative to control	2021	Journal of medicinal chemistry, 05-13, Volume: 64, Issue:9	Synthesis, Molecular Pharmacology, and Structure-Activity Relationships of 3-(Indanoyl)indoles as Selective Cannabinoid Type 2 Receptor Antagonists.
AID1853936	Agonist activity at human CB1 receptor expressed in mouse AtT20 cells incubated for 60 mins by FLIPR membrane potential assay
AID1562931	Agonist activity at MOR/CB1R/CB2R receptor in Wistar rat brain membranes at 10 uM after 60 mins by [35S]-GTPgammaS binding assay relative to control	2019	European journal of medicinal chemistry, Sep-15, Volume: 178	Preparation of bivalent agonists for targeting the mu opioid and cannabinoid receptors.
AID1853934	Displacement of [3H]-CP55940 from human CB1 receptor expressed in human HEK293-EBNA cells incubated for 60 mins by radioligand competitive binding assay based liquid scintillation counter
AID1562938	Agonist activity at CB1R/CB2R in Wistar rat brain membranes after 60 mins by [35S]-GTPgammaS binding assay	2019	European journal of medicinal chemistry, Sep-15, Volume: 178	Preparation of bivalent agonists for targeting the mu opioid and cannabinoid receptors.
AID620214	Activation of CB1 receptor in Wistar rat prelimbic prefrontal cortex assessed as reduction of field excitatory postsynaptic potential amplitude after 20 mins	2011	European journal of medicinal chemistry, Oct, Volume: 46, Issue:10	Novel indole and azaindole (pyrrolopyridine) cannabinoid (CB) receptor agonists: design, synthesis, structure-activity relationships, physicochemical properties and biological activity.
AID1853942	Agonist activity at CB1 receptor (unknown origin) expressed in human HEK293T cells co-expressing beta-arrestin2 assessed as beta-arrestin2 recruitment by measuring maximal luminescence using furimazine as substrate at 100 uM by Nano-Glo live cell reagent
AID1562902	Displacement of [3H]JWH-018 from CB1R/CB2R in Wistar rat brain membranes assessed as dissociation constant by liquid scintillation analysis	2019	European journal of medicinal chemistry, Sep-15, Volume: 178	Preparation of bivalent agonists for targeting the mu opioid and cannabinoid receptors.
AID1562923	Effect on nociception of the contralateral paw in rat model of sodium iodoacetate-induced osteoarthritis paw withdrawal threshold in early phase at 20 ug administered as intrathecal injection measured up to 45 mins by Von Frey test (Rvb = 44 +/- 2.4 g)	2019	European journal of medicinal chemistry, Sep-15, Volume: 178	Preparation of bivalent agonists for targeting the mu opioid and cannabinoid receptors.
AID419194	Displacement of [3H]CP-55940 from CB1 receptor in rat brain by filtration assay	2009	European journal of medicinal chemistry, Jun, Volume: 44, Issue:6	Development of CoMFA and CoMSIA models of affinity and selectivity for indole ligands of cannabinoid CB1 and CB2 receptors.
AID1211513	Displacement of [3H]CP-55,940 from CB1 receptor in B6SJL mouse brain membrane after 90 mins by liquid scintillation spectrophotometric analysis	2012	Drug metabolism and disposition: the biological fate of chemicals, Nov, Volume: 40, Issue:11	Cytochrome P450-mediated oxidative metabolism of abused synthetic cannabinoids found in K2/Spice: identification of novel cannabinoid receptor ligands.
AID419197	Selectivity ratio of pKi for human cloned CB2 receptor to pKi for CB1 receptor in rat brain	2009	European journal of medicinal chemistry, Jun, Volume: 44, Issue:6	Development of CoMFA and CoMSIA models of affinity and selectivity for indole ligands of cannabinoid CB1 and CB2 receptors.
AID1211540	Drug metabolism in human urine assessed as (1-(5-hydroxypentyl)-1H-indol-3-yl)(naphthalen-1-yl)methanone formation by LC-MS/MS analysis	2012	Drug metabolism and disposition: the biological fate of chemicals, Nov, Volume: 40, Issue:11	Cytochrome P450-mediated oxidative metabolism of abused synthetic cannabinoids found in K2/Spice: identification of novel cannabinoid receptor ligands.
AID1127518	Binding affinity to CB1 receptor (unknown origin)	2013	Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21	Therapeutic utility of cannabinoid receptor type 2 (CB(2)) selective agonists.
AID620178	Displacement of [3H]-CP55940 from human CB1 receptor expressed in CHO cells by liquid scintillation counting	2011	European journal of medicinal chemistry, Oct, Volume: 46, Issue:10	Novel indole and azaindole (pyrrolopyridine) cannabinoid (CB) receptor agonists: design, synthesis, structure-activity relationships, physicochemical properties and biological activity.
AID620215	Activation of CB1 receptor in Wistar rat prelimbic prefrontal cortex assessed as reduction of field excitatory postsynaptic potential amplitude after 20 mins relative to baseline	2011	European journal of medicinal chemistry, Oct, Volume: 46, Issue:10	Novel indole and azaindole (pyrrolopyridine) cannabinoid (CB) receptor agonists: design, synthesis, structure-activity relationships, physicochemical properties and biological activity.
AID1767033	Selectivity index, ratio of Ki for human CB1 receptor expressed in CHO cells to Ki for human CB2 receptor expressed in CHO cells	2021	Journal of medicinal chemistry, 05-13, Volume: 64, Issue:9	Synthesis, Molecular Pharmacology, and Structure-Activity Relationships of 3-(Indanoyl)indoles as Selective Cannabinoid Type 2 Receptor Antagonists.
AID1562901	Displacement of [3H]JWH-018 from CB1R/CB2R in Wistar rat brain membranes at 10 uM by liquid scintillation analysis relative to control	2019	European journal of medicinal chemistry, Sep-15, Volume: 178	Preparation of bivalent agonists for targeting the mu opioid and cannabinoid receptors.
AID1853940	Agonist activity at CB1 receptor (unknown origin) expressed in human HEK293T cells co-expressing beta-arrestin2 assessed as beta-arrestin2 recruitment using furimazine as substrate by Nano-Glo live cell reagent assay
AID1211514	Activation of CB1 receptor in B6SJL mouse brain membrane assessed as [35S]-GTPgammaS binding at 10 uM after 30 mins by liquid scintillation spectrophotometric analysis	2012	Drug metabolism and disposition: the biological fate of chemicals, Nov, Volume: 40, Issue:11	Cytochrome P450-mediated oxidative metabolism of abused synthetic cannabinoids found in K2/Spice: identification of novel cannabinoid receptor ligands.
AID1211519	Drug metabolism assessed as human recombinant CYP2E1-mediated (1-(5-hydroxypentyl)-1H-indol-3-yl)(naphthalen-1-yl)methanone formation at 10 uM after 90 mins by LC-MS/MS analysis	2012	Drug metabolism and disposition: the biological fate of chemicals, Nov, Volume: 40, Issue:11	Cytochrome P450-mediated oxidative metabolism of abused synthetic cannabinoids found in K2/Spice: identification of novel cannabinoid receptor ligands.
AID1853937	Agonist activity at human CB2 receptor expressed in mouse AtT20 cells incubated for 60 mins by FLIPR membrane potential assay
AID1853941	Agonist activity at CB2 receptor (unknown origin) expressed in human HEK293T cells co-expressing beta-arrestin2 assessed as beta-arrestin2 recruitment using furimazine as substrate by Nano-Glo live cell reagent assay
AID1853935	Displacement of [3H]-CP55940 from N-terminal 3HA-tagged human CB2 receptor expressed in human HEK293-EBNA cells incubated for 60 mins by radioligand competitive binding assay based liquid scintillation counter
AID1562940	Agonist activity at CB1R/CB2R in Wistar rat brain membranes after 60 mins by [35S]-GTPgammaS binding assay relative to control	2019	European journal of medicinal chemistry, Sep-15, Volume: 178	Preparation of bivalent agonists for targeting the mu opioid and cannabinoid receptors.
AID1211524	Drug metabolism assessed as human recombinant CYP3A4-mediated (1-(4-hydroxypentyl)-1H-indol-3-yl)(naphthalen-1-yl)methanone formation at 10 uM after 90 mins by LC-MS/MS analysis	2012	Drug metabolism and disposition: the biological fate of chemicals, Nov, Volume: 40, Issue:11	Cytochrome P450-mediated oxidative metabolism of abused synthetic cannabinoids found in K2/Spice: identification of novel cannabinoid receptor ligands.
AID1211522	Drug metabolism assessed as human recombinant CYP3A4-mediated (1-(5-hydroxypentyl)-1H-indol-3-yl)(naphthalen-1-yl)methanone formation at 10 uM after 90 mins by LC-MS/MS analysis	2012	Drug metabolism and disposition: the biological fate of chemicals, Nov, Volume: 40, Issue:11	Cytochrome P450-mediated oxidative metabolism of abused synthetic cannabinoids found in K2/Spice: identification of novel cannabinoid receptor ligands.
AID714717	Hypothermic activity in iv dosed Harlan ICR mouse assessed as change in rectal temperature at 30 mins	2012	Bioorganic & medicinal chemistry, Mar-15, Volume: 20, Issue:6	Synthesis and pharmacology of 1-alkyl-3-(1-naphthoyl)indoles: steric and electronic effects of 4- and 8-halogenated naphthoyl substituents.
AID1211527	Drug metabolism assessed as cytochrome b5 (unknown origin)-mediated (5-hydroxy-1-pentyl-1H-indol-3-yl)(naphthalen-1-yl)methanone formation at 10 uM after 90 mins by LC-MS/MS analysis in presence of oxidoreductase	2012	Drug metabolism and disposition: the biological fate of chemicals, Nov, Volume: 40, Issue:11	Cytochrome P450-mediated oxidative metabolism of abused synthetic cannabinoids found in K2/Spice: identification of novel cannabinoid receptor ligands.
AID1562900	Displacement of [3H]JWH-018 from CB1R/CB2R in Wistar rat brain membranes assessed as pseudo-first order rate constant at 10 uM up to 90 mins by liquid scintillation analysis	2019	European journal of medicinal chemistry, Sep-15, Volume: 178	Preparation of bivalent agonists for targeting the mu opioid and cannabinoid receptors.
AID1211521	Drug metabolism assessed as human recombinant CYP2E1-mediated (1-(4-hydroxypentyl)-1H-indol-3-yl)(naphthalen-1-yl)methanone formation at 10 uM after 90 mins by LC-MS/MS analysis	2012	Drug metabolism and disposition: the biological fate of chemicals, Nov, Volume: 40, Issue:11	Cytochrome P450-mediated oxidative metabolism of abused synthetic cannabinoids found in K2/Spice: identification of novel cannabinoid receptor ligands.
AID1562911	Displacement of [3H]WIN-55,212-2 from CB1R/CB2R in Wistar rat brain membranes after 60 mins by liquid scintillation analysis	2019	European journal of medicinal chemistry, Sep-15, Volume: 178	Preparation of bivalent agonists for targeting the mu opioid and cannabinoid receptors.
AID620179	Selectivity ratio of Ki for human CB2 receptor to Ki for human CB1 receptor	2011	European journal of medicinal chemistry, Oct, Volume: 46, Issue:10	Novel indole and azaindole (pyrrolopyridine) cannabinoid (CB) receptor agonists: design, synthesis, structure-activity relationships, physicochemical properties and biological activity.
AID1853943	Agonist activity at CB2 receptor (unknown origin) expressed in human HEK293T cells co-expressing beta-arrestin2 assessed as beta-arrestin2 recruitment by measuring maximal luminescence using furimazine as substrate at 100 uM by Nano-Glo live cell reagent
AID714689	Selectivity ratio of Ki for human CB1 receptor to Ki for human CB2 receptor	2012	Bioorganic & medicinal chemistry, Mar-15, Volume: 20, Issue:6	Synthesis and pharmacology of 1-alkyl-3-(1-naphthoyl)indoles: steric and electronic effects of 4- and 8-halogenated naphthoyl substituents.
AID1211523	Drug metabolism assessed as human recombinant CYP3A4-mediated 5-(3-(1-naphthoyl)-1H-indol-1-yl)pentanoic acid formation at 10 uM after 90 mins by LC-MS/MS analysis	2012	Drug metabolism and disposition: the biological fate of chemicals, Nov, Volume: 40, Issue:11	Cytochrome P450-mediated oxidative metabolism of abused synthetic cannabinoids found in K2/Spice: identification of novel cannabinoid receptor ligands.
AID1632070	Displacement of [3H]-CP55940 from human CB1 receptor	2016	Journal of medicinal chemistry, 08-25, Volume: 59, Issue:16	Peripherally Selective Cannabinoid 1 Receptor (CB1R) Agonists for the Treatment of Neuropathic Pain.
AID1853938	Agonist activity at human CB1 receptor expressed in mouse AtT20 cells assessed as maximal agonist effect by measuring fluorescence at 10 uM incubated for 60 mins by FLIPR membrane potential assay relative to CP55940
AID1562912	Agonist activity at MOR/CB1R/CB2R receptor in Wistar rat brain membranes after 60 mins by [35S]-GTPgammaS binding assay	2019	European journal of medicinal chemistry, Sep-15, Volume: 178	Preparation of bivalent agonists for targeting the mu opioid and cannabinoid receptors.
AID1562924	Effect on nociception of the contralateral paw in rat model of sodium iodoacetate-induced osteoarthritis paw withdrawal threshold in late phase at 20 ug administered as intrathecal injection measured after 60 to 90 mins by Von Frey test (Rvb = 43 +/- 3.4	2019	European journal of medicinal chemistry, Sep-15, Volume: 178	Preparation of bivalent agonists for targeting the mu opioid and cannabinoid receptors.
AID1562907	Displacement of [3H]Ile5,6-deltorphin-2 from DOR in Wistar rat brain membranes after 60 mins by liquid scintillation analysis	2019	European journal of medicinal chemistry, Sep-15, Volume: 178	Preparation of bivalent agonists for targeting the mu opioid and cannabinoid receptors.
AID1853939	Agonist activity at human CB2 receptor expressed in mouse AtT20 cells assessed as maximal agonist effect by measuring fluorescence at 10 uM incubated for 60 mins by FLIPR membrane potential assay relative to CP55940
AID714694	Locomotor activity in iv dosed Harlan ICR mouse from 5 to 15 mins by spontaneous locomotor activity test	2012	Bioorganic & medicinal chemistry, Mar-15, Volume: 20, Issue:6	Synthesis and pharmacology of 1-alkyl-3-(1-naphthoyl)indoles: steric and electronic effects of 4- and 8-halogenated naphthoyl substituents.
AID1211515	Activation of CB1 receptor in B6SJL mouse brain membrane assessed as [35S]-GTPgammaS binding at 10 uM after 30 mins by liquid scintillation spectrophotometric analysis in presence of O-2050	2012	Drug metabolism and disposition: the biological fate of chemicals, Nov, Volume: 40, Issue:11	Cytochrome P450-mediated oxidative metabolism of abused synthetic cannabinoids found in K2/Spice: identification of novel cannabinoid receptor ligands.
AID1211520	Drug metabolism assessed as human recombinant CYP2E1-mediated 5-(3-(1-naphthoyl)-1H-indol-1-yl)pentanoic acid formation at 10 uM after 90 mins by LC-MS/MS analysis	2012	Drug metabolism and disposition: the biological fate of chemicals, Nov, Volume: 40, Issue:11	Cytochrome P450-mediated oxidative metabolism of abused synthetic cannabinoids found in K2/Spice: identification of novel cannabinoid receptor ligands.
AID1211530	Drug metabolism in human urine assessed as (1-(4-hydroxypentyl)-1H-indol-3-yl)(naphthalen-1-yl)methanone formation by LC-MS/MS analysis	2012	Drug metabolism and disposition: the biological fate of chemicals, Nov, Volume: 40, Issue:11	Cytochrome P450-mediated oxidative metabolism of abused synthetic cannabinoids found in K2/Spice: identification of novel cannabinoid receptor ligands.
AID620183	Thermodynamic solubility of the compound in phosphate buffer at pH 7.4 after 24 hrs by HPLC analysis	2011	European journal of medicinal chemistry, Oct, Volume: 46, Issue:10	Novel indole and azaindole (pyrrolopyridine) cannabinoid (CB) receptor agonists: design, synthesis, structure-activity relationships, physicochemical properties and biological activity.
AID1211539	Drug metabolism in human urine assessed as 5-(3-(1-naphthoyl)-1H-indol-1-yl)pentanoic acid formation by LC-MS/MS analysis	2012	Drug metabolism and disposition: the biological fate of chemicals, Nov, Volume: 40, Issue:11	Cytochrome P450-mediated oxidative metabolism of abused synthetic cannabinoids found in K2/Spice: identification of novel cannabinoid receptor ligands.
AID620181	Agonist activity at human CB2 receptor expressed in CHO cells assessed as increase of forskolin-stimulated cAMP accumulation after 20 mins	2011	European journal of medicinal chemistry, Oct, Volume: 46, Issue:10	Novel indole and azaindole (pyrrolopyridine) cannabinoid (CB) receptor agonists: design, synthesis, structure-activity relationships, physicochemical properties and biological activity.
AID419195	Displacement of [3H]CP-55940 from human cloned CB2 receptor by filtration assay	2009	European journal of medicinal chemistry, Jun, Volume: 44, Issue:6	Development of CoMFA and CoMSIA models of affinity and selectivity for indole ligands of cannabinoid CB1 and CB2 receptors.
AID620182	Lipophilicity, log D of the compound at pH 7.4	2011	European journal of medicinal chemistry, Oct, Volume: 46, Issue:10	Novel indole and azaindole (pyrrolopyridine) cannabinoid (CB) receptor agonists: design, synthesis, structure-activity relationships, physicochemical properties and biological activity.
AID1562927	Antiallodynic activity in sodium iodoacetate-induced rat model of osteoarthritis assessed as increase in maximum effect in early phase at 20 ug administered as intrathecal injection measured up to 45 mins by Von Frey test	2019	European journal of medicinal chemistry, Sep-15, Volume: 178	Preparation of bivalent agonists for targeting the mu opioid and cannabinoid receptors.
AID1562899	Displacement of [3H]JWH-018 from CB1R/CB2R in Wistar rat brain membranes assessed as specific binding at 10 uM up to 90 mins by liquid scintillation analysis relative to control	2019	European journal of medicinal chemistry, Sep-15, Volume: 178	Preparation of bivalent agonists for targeting the mu opioid and cannabinoid receptors.
AID1127517	Binding affinity to CB2 receptor (unknown origin)	2013	Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21	Therapeutic utility of cannabinoid receptor type 2 (CB(2)) selective agonists.
AID1562898	Displacement of [3H]JWH-018 from CB1R/CB2R in Wistar rat brain membranes assessed as dissociation rate constant at 10 uM by liquid scintillation analysis	2019	European journal of medicinal chemistry, Sep-15, Volume: 178	Preparation of bivalent agonists for targeting the mu opioid and cannabinoid receptors.
AID620177	Displacement of [3H]-CP55940 from human CB2 receptor expressed in CHO cells by liquid scintillation counting	2011	European journal of medicinal chemistry, Oct, Volume: 46, Issue:10	Novel indole and azaindole (pyrrolopyridine) cannabinoid (CB) receptor agonists: design, synthesis, structure-activity relationships, physicochemical properties and biological activity.
AID1562903	Displacement of [3H]JWH-018 from CB1R/CB2R in Wistar rat brain membranes after 60 mins by liquid scintillation analysis	2019	European journal of medicinal chemistry, Sep-15, Volume: 178	Preparation of bivalent agonists for targeting the mu opioid and cannabinoid receptors.
AID1562906	Displacement of [3H]DAMGO from MOR in Wistar rat brain membranes after 60 mins by liquid scintillation analysis	2019	European journal of medicinal chemistry, Sep-15, Volume: 178	Preparation of bivalent agonists for targeting the mu opioid and cannabinoid receptors.
AID620180	Agonist activity at human CB1 receptor expressed in CHO cells assessed as stimulation of [3H]-arachidonic acid release	2011	European journal of medicinal chemistry, Oct, Volume: 46, Issue:10	Novel indole and azaindole (pyrrolopyridine) cannabinoid (CB) receptor agonists: design, synthesis, structure-activity relationships, physicochemical properties and biological activity.
AID714707	Antinociceptive activity in iv dosed Harlan ICR mouse assessed as latency to heat-induced tail flicking at 20 mins	2012	Bioorganic & medicinal chemistry, Mar-15, Volume: 20, Issue:6	Synthesis and pharmacology of 1-alkyl-3-(1-naphthoyl)indoles: steric and electronic effects of 4- and 8-halogenated naphthoyl substituents.
AID1562930	Displacement of [3H]JWH-018 from CB1R/CB2R in Wistar rat brain membranes assessed as maximum efficacy at 10 uM by liquid scintillation analysis	2019	European journal of medicinal chemistry, Sep-15, Volume: 178	Preparation of bivalent agonists for targeting the mu opioid and cannabinoid receptors.
AID714949	Induction of catalepsy in mouse by ring immobility test	2012	Bioorganic & medicinal chemistry, Mar-15, Volume: 20, Issue:6	Synthesis and pharmacology of 1-alkyl-3-(1-naphthoyl)indoles: steric and electronic effects of 4- and 8-halogenated naphthoyl substituents.
AID1211536	Drug metabolism in human liver microsomes assessed as (7-hydroxy-1-pentyl-1H-indol-3-yl)(naphthalen-1-yl)methanone formation at 10 uM after 20 mins by LC-MS/MS analysis	2012	Drug metabolism and disposition: the biological fate of chemicals, Nov, Volume: 40, Issue:11	Cytochrome P450-mediated oxidative metabolism of abused synthetic cannabinoids found in K2/Spice: identification of novel cannabinoid receptor ligands.
AID1211534	Drug metabolism in human liver microsomes assessed as (6-hydroxy-1-pentyl-1H-indol-3-yl)(naphthalen-1-yl)methanone formation at 10 uM after 20 mins by LC-MS/MS analysis	2012	Drug metabolism and disposition: the biological fate of chemicals, Nov, Volume: 40, Issue:11	Cytochrome P450-mediated oxidative metabolism of abused synthetic cannabinoids found in K2/Spice: identification of novel cannabinoid receptor ligands.
AID493017	Wombat Data for BeliefDocking	2003	Bioorganic & medicinal chemistry, Feb-20, Volume: 11, Issue:4	3-Indolyl-1-naphthylmethanes: new cannabimimetic indoles provide evidence for aromatic stacking interactions with the CB(1) cannabinoid receptor.
AID1346701	Human CB1 receptor (Cannabinoid receptors)	1999	The Journal of pharmacology and experimental therapeutics, Nov, Volume: 291, Issue:2	The third transmembrane helix of the cannabinoid receptor plays a role in the selectivity of aminoalkylindoles for CB2, peripheral cannabinoid receptor.
AID1346728	Human CB2 receptor (Cannabinoid receptors)	1999	The Journal of pharmacology and experimental therapeutics, Nov, Volume: 291, Issue:2	The third transmembrane helix of the cannabinoid receptor plays a role in the selectivity of aminoalkylindoles for CB2, peripheral cannabinoid receptor.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	1 (0.64)	18.2507
2000's	2 (1.28)	29.6817
2010's	130 (83.33)	24.3611
2020's	23 (14.74)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	3 (1.89%)	5.53%
Reviews	10 (6.29%)	6.00%
Case Studies	11 (6.92%)	4.05%
Observational	0 (0.00%)	0.25%
Other	135 (84.91%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
gamma-aminobutyric acid gamma-Aminobutyric Acid: The most common inhibitory neurotransmitter in the central nervous system.. gamma-aminobutyric acid : A gamma-amino acid that is butanoic acid with the amino substituent located at C-4.	2.11	1	amino acid zwitterion; gamma-amino acid; monocarboxylic acid	human metabolite; neurotransmitter; Saccharomyces cerevisiae metabolite; signalling molecule
methanol Methanol: A colorless, flammable liquid used in the manufacture of FORMALDEHYDE and ACETIC ACID, in chemical synthesis, antifreeze, and as a solvent. Ingestion of methanol is toxic and may cause blindness.. primary alcohol : A primary alcohol is a compound in which a hydroxy group, -OH, is attached to a saturated carbon atom which has either three hydrogen atoms attached to it or only one other carbon atom and two hydrogen atoms attached to it.. methanol : The primary alcohol that is the simplest aliphatic alcohol, comprising a methyl and an alcohol group.	2.57	2	alkyl alcohol; one-carbon compound; primary alcohol; volatile organic compound	amphiprotic solvent; Escherichia coli metabolite; fuel; human metabolite; mouse metabolite; Mycoplasma genitalium metabolite
am 251 AM 251: an analog of SR141716A; structure given in first source. AM-251 : A carbohydrazide obtained by formal condensation of the carboxy group of 1-(2,4-dichlorophenyl)-5-(4-iodophenyl)-4-methyl-1H-pyrazole-3-carboxylic acid with the amino group of 1-aminopiperidine. An antagonist at the CB1 cannabinoid receptor.	3.39	6	amidopiperidine; carbohydrazide; dichlorobenzene; organoiodine compound; pyrazoles	antidepressant; antineoplastic agent; apoptosis inducer; CB1 receptor antagonist
diazepam Diazepam: A benzodiazepine with anticonvulsant, anxiolytic, sedative, muscle relaxant, and amnesic properties and a long duration of action. Its actions are mediated by enhancement of GAMMA-AMINOBUTYRIC ACID activity.. diazepam : A 1,4-benzodiazepinone that is 1,3-dihydro-2H-1,4-benzodiazepin-2-one substituted by a chloro group at position 7, a methyl group at position 1 and a phenyl group at position 5.	2.41	1	1,4-benzodiazepinone; organochlorine compound	anticonvulsant; anxiolytic drug; environmental contaminant; sedative; xenobiotic
fentanyl Fentanyl: A potent narcotic analgesic, abuse of which leads to habituation or addiction. It is primarily a mu-opioid agonist. Fentanyl is also used as an adjunct to general anesthetics, and as an anesthetic for induction and maintenance. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1078). fentanyl : A monocarboxylic acid amide resulting from the formal condensation of the aryl amino group of N-phenyl-1-(2-phenylethyl)piperidin-4-amine with propanoic acid.	2.31	1	anilide; monocarboxylic acid amide; piperidines	adjuvant; anaesthesia adjuvant; anaesthetic; intravenous anaesthetic; mu-opioid receptor agonist; opioid analgesic
mianserin Mianserin: A tetracyclic compound with antidepressant effects. It may cause drowsiness and hematological problems. Its mechanism of therapeutic action is not well understood, although it apparently blocks alpha-adrenergic, histamine H1, and some types of serotonin receptors.. mianserin : A dibenzoazepine (specifically 1,2,3,4,10,14b-hexahydrodibenzo[c,f]pyrazino[1,2-a]azepine) methyl-substituted on N-2. Closely related to (and now mostly superseded by) the tetracyclic antidepressant mirtazapinean, it is an atypical antidepressant used in the treatment of depression throughout Europe and elsewhere.	2.13	1	dibenzoazepine	adrenergic uptake inhibitor; alpha-adrenergic antagonist; antidepressant; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; geroprotector; H1-receptor antagonist; histamine agonist; sedative; serotonergic antagonist
sulfaphenazole Sulfaphenazole: A sulfonilamide anti-infective agent.. sulfaphenazole : A sulfonamide that is sulfanilamide in which the sulfonamide nitrogen is substituted by a 1-phenyl-1H-pyrazol-5-yl group. It is a selective inhibitor of cytochrome P450 (CYP) 2C9 isozyme, and antibacterial agent.	2.08	1	primary amino compound; pyrazoles; substituted aniline; sulfonamide antibiotic; sulfonamide	antibacterial drug; EC 1.14.13.181 (13-deoxydaunorubicin hydroxylase) inhibitor; EC 1.14.13.67 (quinine 3-monooxygenase) inhibitor; P450 inhibitor
corticosterone [no description available]	2.08	1	11beta-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(4) steroid; C21-steroid; glucocorticoid; primary alpha-hydroxy ketone	human metabolite; mouse metabolite
pentylenetetrazole Pentylenetetrazole: A pharmaceutical agent that displays activity as a central nervous system and respiratory stimulant. It is considered a non-competitive GAMMA-AMINOBUTYRIC ACID antagonist. Pentylenetetrazole has been used experimentally to study seizure phenomenon and to identify pharmaceuticals that may control seizure susceptibility.. pentetrazol : An organic heterobicyclic compound that is 1H-tetrazole in which the hydrogens at positions 1 and 5 are replaced by a pentane-1,5-diyl group. A central and respiratory stimulant, it was formerly used for the treatment of cough and other respiratory tract disorders, cardiovascular disorders including hypotension, and pruritis.	2.41	1	organic heterobicyclic compound; organonitrogen heterocyclic compound
valine Valine: A branched-chain essential amino acid that has stimulant activity. It promotes muscle growth and tissue repair. It is a precursor in the penicillin biosynthetic pathway.. valine : A branched-chain amino acid that consists of glycine in which one of the hydrogens attached to the alpha-carbon is substituted by an isopropyl group.. L-valine : The L-enantiomer of valine.	4.01	3	L-alpha-amino acid zwitterion; L-alpha-amino acid; proteinogenic amino acid; pyruvate family amino acid; valine	algal metabolite; Escherichia coli metabolite; human metabolite; micronutrient; mouse metabolite; nutraceutical; Saccharomyces cerevisiae metabolite
quinuclidines Quinuclidines: A class of organic compounds which contain two rings that share a pair of bridgehead carbon atoms and contains an amine group.	2.15	1	quinuclidines; saturated organic heterobicyclic parent
cyclohexanol Cyclohexanols: Monohydroxy derivatives of cyclohexanes that contain the general formula R-C6H11O. They have a camphorlike odor and are used in making soaps, insecticides, germicides, dry cleaning, and plasticizers.. cyclohexanols : An alcohol in which one or more hydroxy groups are attached to a cyclohexane skeleton.	4.58	7	cyclohexanols; secondary alcohol	solvent
n-pentanoic acid n-pentanoic acid: RN given refers to unlabeled parent cpd. valeric acid : A straight-chain saturated fatty acid containing five carbon atoms.	3.02	4	short-chain fatty acid; straight-chain saturated fatty acid	plant metabolite
pyrroles 1H-pyrrole : A tautomer of pyrrole that has the double bonds at positions 2 and 4.. pyrrole : A five-membered monocyclic heteroarene comprising one NH and four CH units which forms the parent compound of the pyrrole group of compounds. Its five-membered ring structure has three tautomers. A 'closed class'.. azole : Any monocyclic heteroarene consisting of a five-membered ring containing nitrogen. Azoles can also contain one or more other non-carbon atoms, such as nitrogen, sulfur or oxygen.	3.19	1	pyrrole; secondary amine
indazoles Indazoles: A group of heterocyclic aromatic organic compounds consisting of the fusion of BENZENE and PYRAZOLES.	5.38	9	indazole
adamantane Adamantane: A tricyclo bridged hydrocarbon.	4.33	5	adamantanes; polycyclic alkane
limestone Calcium Carbonate: Carbonic acid calcium salt (CaCO3). An odorless, tasteless powder or crystal that occurs in nature. It is used therapeutically as a phosphate buffer in hemodialysis patients and as a calcium supplement.. calcium carbonate : A calcium salt with formula CCaO3.	2.41	1	calcium salt; carbonate salt; inorganic calcium salt; one-carbon compound	antacid; fertilizer; food colouring; food firming agent
phenylpropanolamine Phenylpropanolamine: A sympathomimetic that acts mainly by causing release of NOREPINEPHRINE but also has direct agonist activity at some adrenergic receptors. It is most commonly used as a nasal vasoconstrictor and an appetite depressant.. phenylpropanolamine : An amphetamine in which the parent 1-phenylpropan-2-amine skeleton is substituted at position 1 with an hydroxy group. A decongestant and appetite suppressant, it is commonly used in prescription and over-the-counter cough and cold preparations.. (-)-norephedrine : An amphetamine that is propylbenzene substituted by a hydroxy group at position 1 and by an amino group at position 2 (the 1R,2S-stereoisomer). It is a plant alkaloid.	2.08	1	amphetamines; phenethylamine alkaloid	plant metabolite
methamphetamine Methamphetamine: A central nervous system stimulant and sympathomimetic with actions and uses similar to DEXTROAMPHETAMINE. The smokable form is a drug of abuse and is referred to as crank, crystal, crystal meth, ice, and speed.. methamphetamine : A member of the class of amphetamines in which the amino group of (S)-amphetamine carries a methyl substituent.	2.49	2	amphetamines; secondary amine	central nervous system stimulant; environmental contaminant; neurotoxin; psychotropic drug; xenobiotic
alpha-naphthoflavone alpha-naphthoflavone: inhibits P4501A1 and P4501A2; stimulates some activities of P4503A4. alpha-naphthoflavone : An extended flavonoid resulting from the formal fusion of a benzene ring with the h side of flavone. A synthetic compound, it is an inhibitor of aromatase (EC 1.14.14.14).	2.08	1	extended flavonoid; naphtho-gamma-pyrone; organic heterotricyclic compound	aryl hydrocarbon receptor agonist; aryl hydrocarbon receptor antagonist; EC 1.14.14.14 (aromatase) inhibitor
dronabinol Dronabinol: A psychoactive compound extracted from the resin of Cannabis sativa (marihuana, hashish). The isomer delta-9-tetrahydrocannabinol (THC) is considered the most active form, producing characteristic mood and perceptual changes associated with this compound.. Delta(9)-tetrahydrocannabinol : A diterpenoid that is 6a,7,8,10a-tetrahydro-6H-benzo[c]chromene substituted at position 1 by a hydroxy group, positions 6, 6 and 9 by methyl groups and at position 3 by a pentyl group. The principal psychoactive constituent of the cannabis plant, it is used for treatment of anorexia associated with AIDS as well as nausea and vomiting associated with cancer chemotherapy.	7.14	33	benzochromene; diterpenoid; phytocannabinoid; polyketide	cannabinoid receptor agonist; epitope; hallucinogen; metabolite; non-narcotic analgesic
gold Gold: A yellow metallic element with the atomic symbol Au, atomic number 79, and atomic weight 197. It is used in jewelry, goldplating of other metals, as currency, and in dental restoration. Many of its clinical applications, such as ANTIRHEUMATIC AGENTS, are in the form of its salts.	2.31	1	copper group element atom; elemental gold
deuterium Deuterium: The stable isotope of hydrogen. It has one neutron and one proton in the nucleus.	2.49	2	dihydrogen
glutamic acid Glutamic Acid: A non-essential amino acid naturally occurring in the L-form. Glutamic acid is the most common excitatory neurotransmitter in the CENTRAL NERVOUS SYSTEM.. glutamic acid : An alpha-amino acid that is glutaric acid bearing a single amino substituent at position 2.	2.11	1	glutamic acid; glutamine family amino acid; L-alpha-amino acid; proteinogenic amino acid	Escherichia coli metabolite; ferroptosis inducer; micronutrient; mouse metabolite; neurotransmitter; nutraceutical
pravadoline [no description available]	2.46	2
remifentanil Remifentanil: A piperidine-propionate derivative and opioid analgesic structurally related to FENTANYL. It functions as a short-acting MU OPIOID RECEPTOR agonist, and is used as an analgesic during induction or maintenance of general anesthesia, following surgery, during childbirth, and in mechanically ventilated patients under intensive care.. remifentanil : A piperidinecarboxylate ester that is methyl piperidine-4-carboxylate in which the hydrogen attached to the nitrogen is substituted by a 3-methoxy-3-oxopropyl group and the hydrogen at position 4 is substituted the nitrogen of N-propanoylaniline.	2.63	2	alpha-amino acid ester; anilide; monocarboxylic acid amide; piperidinecarboxylate ester	intravenous anaesthetic; mu-opioid receptor agonist; opioid analgesic; sedative
cathinone cathinone: alkaloid from khat shrub, Catha edulis; RN given refers to parent cpd without isomeric designation. cathinone : The S stereoisomer of 2-aminopropiophenone.	2.08	1	2-aminopropiophenone; monoamine alkaloid	central nervous system stimulant; psychotropic drug
4-hydroxyindole hydroxyindoles : Any member of the class of indoles carrying at least one hydroxy group.	2.13	1	hydroxyindoles; phenols
glucuronic acid Glucuronic Acid: A sugar acid formed by the oxidation of the C-6 carbon of GLUCOSE. In addition to being a key intermediate metabolite of the uronic acid pathway, glucuronic acid also plays a role in the detoxification of certain drugs and toxins by conjugating with them to form GLUCURONIDES.. D-glucuronic acid : The D-enantiomer of glucuronic acid.. D-glucopyranuronic acid : A D-glucuronic acid in cyclic pyranose form.	2.06	1	D-glucuronic acid	algal metabolite
sr141716 [no description available]	3.53	7	amidopiperidine; carbohydrazide; dichlorobenzene; monochlorobenzenes; pyrazoles	anti-obesity agent; appetite depressant; CB1 receptor antagonist
cp-55,940 [no description available]	4.1	4
1,1-dimethylheptyl-11-hydroxytetrahydrocannabinol HU 211: structure given in first source; HU 211 is active & HU 210 is inactive as canibinoids; functional N-methyl-D-aspartate receptor blocker; RN given is for (6aS-trans)-isomer	3.65	2
trans-1,2-dihydro-1,2-naphthalenediol trans-1,2-dihydro-1,2-naphthalenediol: structure in first source. (1S,2S)-1,2-dihydronaphthalene-1,2-diol : The (1S,2S)-isomer of trans-1,2-dihydronaphthalene-1,2-diol.	2.41	1	trans-1,2-dihydronaphthalene-1,2-diol
2-palmitoylglycerol 2-palmitoylglycerol: increases 2-arachidonoyl-glycerol cannabinoid activity. 2-palmitoylglycerol : A 2-monoglyceride where the acyl group is hexadecanoyl (palmitoyl).	2.13	1	2-acylglycerol 16:0	algal metabolite
3-(2-hydroxy-4-(1,1-dimethylheptylphenyl)cyclohexan-1-ol) CP 47497: cannabimimetic agent; structure given in first source	4.1	4	alkylbenzene; ring assembly
norpseudoephedrine norpseudoephedrine: major metabolite of diethylpropion in man under acidic urine conditions; RN given refers to cpd without isomeric designation;. cathine : An amphetamine that is propylbenzene substituted by a hydroxy group at position 1 and by an amino group at position 2 (the 1S,2S-stereoisomer).	2.08	1	amphetamines; phenethylamine alkaloid	central nervous system stimulant; plant metabolite; psychotropic drug
cocaine Cocaine: An alkaloid ester extracted from the leaves of plants including coca. It is a local anesthetic and vasoconstrictor and is clinically used for that purpose, particularly in the eye, ear, nose, and throat. It also has powerful central nervous system effects similar to the amphetamines and is a drug of abuse. Cocaine, like amphetamines, acts by multiple mechanisms on brain catecholaminergic neurons; the mechanism of its reinforcing effects is thought to involve inhibition of dopamine uptake.. cocaine : A tropane alkaloid obtained from leaves of the South American shrub Erythroxylon coca.	2.66	2	benzoate ester; methyl ester; tertiary amino compound; tropane alkaloid	adrenergic uptake inhibitor; central nervous system stimulant; dopamine uptake inhibitor; environmental contaminant; local anaesthetic; mouse metabolite; plant metabolite; serotonin uptake inhibitor; sodium channel blocker; sympathomimetic agent; vasoconstrictor agent; xenobiotic
enkephalin, leucine Enkephalin, Leucine: One of the endogenous pentapeptides with morphine-like activity. It differs from MET-ENKEPHALIN in the LEUCINE at position 5. Its first four amino acid sequence is identical to the tetrapeptide sequence at the N-terminal of BETA-ENDORPHIN.. Leu-enkephalin : A pentapeptide comprising L-tyrosine, glycine, glycine, L-phenylalanine and L-leucine residues joined in sequence by peptide linkages. It is an endogenous opioid peptide produced in vertebrate species, including rodents, primates and humans that results from decomposition of proenkephalin or dynorphin and exhibits antinociceptive properties.	2.21	1	pentapeptide; peptide zwitterion	analgesic; delta-opioid receptor agonist; human metabolite; mu-opioid receptor agonist; neurotransmitter; rat metabolite
6-hydroxyindole 6-hydroxyindole: structure in first source	2.08	1
delta-8-tetrahydrocannabinol [no description available]	3.18	1	1-benzopyran
cannabidiol Cannabidiol: Compound isolated from Cannabis sativa extract.. cannabidiol : An cannabinoid that is cyclohexene which is substituted by a methyl group at position 1, a 2,6-dihydroxy-4-pentylphenyl group at position 3, and a prop-1-en-2-yl group at position 4.	3.61	2	olefinic compound; phytocannabinoid; resorcinols	antimicrobial agent; plant metabolite
lenabasum lenabasum: a CB2 cannabinoid receptor agonist; structure in first source	3.18	1
jhw 015 [no description available]	4.61	4	indolecarboxamide
am 630 iodopravadoline: an aminoalkylindole; a competitive cannabinoid receptor antagonist; structure given in first source	4	3	N-acylindole
3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol 3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol: (-)-CP-55,940 and (+)-CP-56,667 are enantiomers; RN refers to CP-55,940	2.79	3	alkylbenzene; ring assembly
anandamide anandamide : An N-acylethanolamine 20:4 resulting from the formal condensation of carboxy group of arachidonic acid with the amino group of ethanolamine.	3.61	2	endocannabinoid; N-acylethanolamine 20:4	human blood serum metabolite; neurotransmitter; vasodilator agent
arachidonyl dopamine arachidonyl dopamine: a ligand for the vanilloid receptor VR1	3.18	1	catechols; fatty amide; N-(fatty acyl)-dopamine; secondary carboxamide
glyceryl 2-arachidonate glyceryl 2-arachidonate: binds to cannabinoid receptors; structure in first source. 2-arachidonoylglycerol : An endocannabinoid and an endogenous agonist of the cannabinoid receptors (CB1 and CB2). It is an ester formed from omega-6-arachidonic acid and glycerol.	3.61	2	2-acylglycerol 20:4; endocannabinoid	human metabolite
n-oleoylethanolamine N-oleoylethanolamine: ceramidase inhibitor. oleoyl ethanolamide : An N-(long-chain-acyl)ethanolamine that is the ethanolamide of oleic acid. The monounsaturated analogue of the endocannabinoid anandamide.	2.13	1	endocannabinoid; N-(long-chain-acyl)ethanolamine; N-acylethanolamine 18:1	EC 3.5.1.23 (ceramidase) inhibitor; geroprotector; PPARalpha agonist
nabilone nabilone: cannabinol deriv; RN given refers to cpd without isomeric designation; structure	3.18	1
naloxone Naloxone: A specific opiate antagonist that has no agonist activity. It is a competitive antagonist at mu, delta, and kappa opioid receptors.. naloxone : A synthetic morphinane alkaloid that is morphinone in which the enone double bond has been reduced to a single bond, the hydrogen at position 14 has been replaced by a hydroxy group, and the methyl group attached to the nitrogen has been replaced by an allyl group. A specific opioid antagonist, it is used (commonly as its hydrochloride salt) to reverse the effects of opioids, both following their use of opioids during surgery and in cases of known or suspected opioid overdose.	2.21	1	morphinane alkaloid; organic heteropentacyclic compound; tertiary alcohol	antidote to opioid poisoning; central nervous system depressant; mu-opioid receptor antagonist
oxycodone Oxycodone: A semisynthetic derivative of CODEINE.. oxycodone : A semisynthetic opioid of formula C18H21NO4 that is derived from thebaine. It is a moderately potent opioid analgesic, generally used for relief of moderate to severe pain.	2.21	1	organic heteropentacyclic compound; semisynthetic derivative	antitussive; mu-opioid receptor agonist; opioid analgesic
morphine Meconium: The thick green-to-black mucilaginous material found in the intestines of a full-term fetus. It consists of secretions of the INTESTINAL GLANDS; BILE PIGMENTS; FATTY ACIDS; AMNIOTIC FLUID; and intrauterine debris. It constitutes the first stools passed by a newborn.	2.21	1	morphinane alkaloid; organic heteropentacyclic compound; tertiary amino compound	anaesthetic; drug allergen; environmental contaminant; geroprotector; mu-opioid receptor agonist; opioid analgesic; plant metabolite; vasodilator agent; xenobiotic
arachidonyl-2-chloroethylamide arachidonyl-2-chloroethylamide: a potent and selective agonist of the neuronal cannabinoid receptor; structure in first source. arachidonyl-2'-chloroethylamide : A fatty amide obtained by the formal condensation of arachidonic acid with 2-chloroethanamine. It is a potent agonist of the CB1 receptor (Ki = 1.4 nM) and also has a low affinity for the CB2 receptor (Ki = 3100 nM).	3.18	1	fatty amide; organochlorine compound; secondary carboxamide; synthetic cannabinoid	CB1 receptor agonist; CB2 receptor agonist; neuroprotective agent
arachidonylcyclopropylamide arachidonylcyclopropylamide: a potent and selective agonist of neuronal cannabinoid receptor; structure in first source	3.18	1
endomorphin 1 endomorphin 1: isolated from bovine brain	2.21	1	oligopeptide
endomorphin 2 endomorphin 2: isolated from bovine brain	2.21	1
l 759633 L 759633: structure in first source	3.18	1	1-benzopyran
(3r)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone WIN 55212-2 : A organic heterotricyclic compound that is 5-methyl-3-(morpholin-4-ylmethyl)-2,3-dihydro[1,4]oxazino[2,3,4-hi]indole substituted at position 6 by a 1-naphthylcarbonyl group.	3.86	3	morpholines; naphthyl ketone; organic heterotricyclic compound; synthetic cannabinoid	analgesic; apoptosis inhibitor; neuroprotective agent
2-oleoylglycerol 2-oleoylglycerol : A 2-monoglyceride where the acyl group is (9Z)-octadecenoyl.	2.13	1	2-acylglycerol 18:1; monooleoylglycerol
heroin Heroin: A narcotic analgesic that may be habit-forming. It is a controlled substance (opium derivative) listed in the U.S. Code of Federal Regulations, Title 21 Parts 329.1, 1308.11 (1987). Sale is forbidden in the United States by Federal statute. (Merck Index, 11th ed). heroin : A morphinane alkaloid that is morphine bearing two acetyl substituents on the O-3 and O-6 positions. As with other opioids, heroin is used as both an analgesic and a recreational drug. Frequent and regular administration is associated with tolerance and physical dependence, which may develop into addiction. Its use includes treatment for acute pain, such as in severe physical trauma, myocardial infarction, post-surgical pain, and chronic pain, including end-stage cancer and other terminal illnesses.	2.72	2	morphinane alkaloid	mu-opioid receptor agonist; opioid analgesic; prodrug
tyrosyl alanyl-glycyl-phenylalaninamide tyrosyl alanyl-glycyl-phenylalaninamide: tetrapeptide opiate	2.21	1
virodhamine virodhamine: arachidonic acid and ethanolamine joined by an ester linkage, like anandamide with oxygen and nitrogen reversed; an endocannabinoid from rat; structure in first source	3.18	1	fatty acid ester
am-356 methanandamide: structure given in first source; RN given refers to (all-Z)-(+-)-isomer	3.57	2	fatty amide
noladin ether noladin ether: a cannabinoid CB1 receptor agonist; structure in first source. 2-arachidonyl glyceryl ether : A monoalkylglycerol that is glycerol which is substituted by a (5Z,8Z,11Z,14Z)-icosa-5,8,11,14-tetraen-1-yl group at position 2.	3.18	1	2-alkylglycerol; endocannabinoid; monoalkylglycerol
am 404 [no description available]	2.13	1	anilide
omdm-2 cpd OMDM-2 cpd: structure in first source	2.13	1
jwh-133 1,1-dimethylbutyl-1-deoxy-Delta(9)-THC: a CB2 receptor agonists; no further information available on 8/2001. JWH-133 : A dibenzopyran that is Delta(9)-tetrahydrocannabinol which is lacking the hydroxy group and in which the pentyl group at position 3 has been replaced by a 1,1-dimethylbutyl group. A potent and highly selective CB2 receptor agonist.	3.18	1	benzochromene; dibenzopyran; organic heterotricyclic compound	analgesic; anti-inflammatory agent; antineoplastic agent; apoptosis inhibitor; CB2 receptor agonist; opioid analgesic; vasodilator agent
hu 210 [no description available]	3.9	3	1-benzopyran
am 694 1-(5-fluoropentyl)-3-(2-iodobenzoyl)indole : A member of the class of indoles that is 1H-indole which is substituted at position 1 by a 5-fluoropentyl group and a position 3 by an o-fluorobenzoyl group. It is a selective agonist for the CB1 cannabinoid receptor; Ki values for the CB1 and CB2 receptors are 0.08 and 1.44 nM, respectively.	2.48	2	aromatic ketone; indoles; organofluorine compound; organoiodine compound; synthetic cannabinoid	cannabinoid receptor agonist
1-(2,3-dichlorobenzoyl)-5-methoxy-2-methyl-(2-(mopholin-4-yl)ethyl)-1h-indole [no description available]	3.18	1	N-acylindole
am 1241 AM 1241: a CB(2) receptor-selective agonist; no further information available 11/2001	3.18	1
1-(2,4-dichlorophenyl)-6-methyl-N-(1-piperidinyl)-4H-indeno[1,2-c]pyrazole-3-carboxamide [no description available]	3.18	1	pyrazoles; ring assembly
omdm-1 cpd OMDM-1 cpd: structure in first source	2.13	1
jwh-073 [no description available]	6.51	32	indolecarboxamide
hu 308 HU 308: a specific agonist for CB(2), a peripheral cannabinoid receptor; structure in first source. HU-308 : A carbobicyclic compound that is bicyclo[3.1.1]hept-2-ene which is substituted by a hydroxymethyl group at position 2, a 2,6-dimethoxy-4-(2-methyloctan-2-yl)phenyl group at position 4, and two methyl groups at position 6 (the 1S,4S,5S stereoisomer). A highly selective and effective cannabinoid type-2 agonist and the enantiomer of HU-433.	3.18	1	aromatic ether; bridged compound; carbobicyclic compound; primary allylic alcohol; synthetic cannabinoid	anti-inflammatory agent; antihypertensive agent; apoptosis inhibitor; bone density conservation agent; CB2 receptor agonist
bms 309403 [no description available]	2.13	1
a-836339 A-836339: structure in first source	3.18	1
jzl 184 JZL 184: inhibits monoacylglycerol lipase; structure in first source	2.17	1	benzodioxoles
piperidines Piperidines: A family of hexahydropyridines.	3.73	9
jwh 250 [no description available]	2.05	1
jwh-122 (4-methyl-1-naphthyl)-(1-pentylindol-3-yl)methanone: structure in first source	3.71	9
hemopressin hemopressin: hemoglobin alpha-chain fragment	2.21	1
ur-144 (1-pentyl-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone: structure in first source	3.23	5
mephedrone mephedrone: a beta-keto (bk) designer drug; Central Nervous System Stimulants. mephedrone : An aromatic ketone that is propiophenone substituted at C-4 and at C-beta with methyl and methylamino groups respectively. It is a synthetic stimulant and entactogen drug of the amphetamine and cathinone classes.	2.08	1	amphetamines; aromatic ketone; secondary amino compound	environmental contaminant; xenobiotic
jwh-210 4-ethylnaphthalen-1-yl-(1-pentylindol-3-yl)methanone: a cannabimimetic; structure in first source	3.34	6	indolecarboxamide
methylone [no description available]	2.08	1	benzodioxoles
jwh 019 (1-hexyl-1H-indol-3-yl)-1-naphthalenylmethanone: a synthetic cannabinoid; structure in first source	2.78	3
AM2201 1-(5-fluoropentyl)-3-(1-naphthoyl)indole: a cannabimimetic; structure in first source	5.34	16	indolecarboxamide
s-777469 S-777469: an orally available cannabinoid receptor CB2 agonist as an antipruritic agent; structure in first source	3.18	1
sts-135 N-(adamantan-1-yl)-1-(5-fluoropentyl)-1H-indole-3-carboxamide: a synthetic cannabinoid; structure in first source	2.52	2	indolecarboxamide
AKB48 N-(1-adamantyl)-1-pentylindazole-3-carboxamide: a synthetic cannabinoid; structure in first source	3.64	2	aromatic amide; indazoles
xlr-11 XLR-11: synthetic cannabinoid; structure in first source	3.07	4
pentedrone pentedrone: structure in first source	2.08	1
am4113 AM4113: a cannabinoid CB1 receptor neutral antagonist	2.15	1
1-pentyl-1h-indole-3-carboxylic acid 8-quinolinyl ester 1-pentyl-1H-indole-3-carboxylic acid 8-quinolinyl ester: a recreational synthetic cannabinoid; structure in first source	2.57	2
n-(1-adamantyl)-1-(5-fluoropentyl)-1h-indazole-3-carboxamide N-(1-adamantyl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide: a cannabinoid receptor agonist; structure in first source	2.83	3	aromatic amide; indazoles
n-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1h-indazole-3-carboxamide N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide: a synthetic cannabinoid known as black mamba	2.11	1
n-(1-amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1h-indazole-3-carboxamide N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide: a street drug; structure in first source	3.73	2
n-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-1h-indazole-3-carboxamide N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide: a street drug; structure in first source	2.69	2

Condition	Relationship Strength	Studies	Trials
Nerve Pain [description not available]	2.13	1	0
Neuralgia Intense or aching pain that occurs along the course or distribution of a peripheral or cranial nerve.	2.13	1	0
Congenital Zika Syndrome [description not available]	2.25	1	0
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	2.25	1	0
Zika Virus Infection A viral disease transmitted by the bite of AEDES mosquitoes infected with ZIKA VIRUS. Its mild DENGUE-like symptoms include fever, rash, headaches and ARTHRALGIA. The viral infection during pregnancy, in rare cases, is associated with congenital brain and ocular abnormalities, called Congenital Zika Syndrome, including MICROCEPHALY and may also lead to GUILLAIN-BARRE SYNDROME.	2.25	1	0
Chemical Dependence [description not available]	5.76	18	0
Absence Seizure [description not available]	4.55	8	0
Seizures Clinical or subclinical disturbances of cortical function due to a sudden, abnormal, excessive, and disorganized discharge of brain cells. Clinical manifestations include abnormal motor, sensory and psychic phenomena. Recurrent seizures are usually referred to as EPILEPSY or seizure disorder.	4.55	8	0
Substance-Related Disorders Disorders related to substance use or abuse.	5.76	18	0
Tachyarrhythmia [description not available]	2.54	2	0
Tachycardia Abnormally rapid heartbeat, usually with a HEART RATE above 100 beats per minute for adults. Tachycardia accompanied by disturbance in the cardiac depolarization (cardiac arrhythmia) is called tachyarrhythmia.	2.54	2	0
Pregnancy The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH.	2.54	2	0
Addiction, Opioid [description not available]	2.63	2	0
Opioid-Related Disorders Disorders related to or resulting from abuse or misuse of OPIOIDS.	2.63	2	0
Cognitive Decline [description not available]	2.31	1	0
Developmental Psychomotor Disorders [description not available]	2.31	1	0
Cognitive Dysfunction Diminished or impaired mental and/or intellectual function.	2.31	1	0
Psychoses [description not available]	3.93	2	1
Psychotic Disorders Disorders in which there is a loss of ego boundaries or a gross impairment in reality testing with delusions or prominent hallucinations. (From DSM-IV, 1994)	3.93	2	1
Drug Withdrawal Symptoms [description not available]	3.73	3	0
Cannabis Abuse [description not available]	4.1	5	0
Marijuana Abuse Use of marijuana associated with abnormal psychological, social, and or occupational functioning.	4.1	5	0
Substance Withdrawal Syndrome Physiological and psychological symptoms associated with withdrawal from the use of a drug after prolonged administration or habituation. The concept includes withdrawal from smoking or drinking, as well as withdrawal from an administered drug.	3.73	3	0
Hypothermia, Accidental [description not available]	4.4	7	0
Ache [description not available]	2.08	1	0
Hypothermia Lower than normal body temperature, especially in warm-blooded animals.	4.4	7	0
Pain An unpleasant sensation induced by noxious stimuli which are detected by NERVE ENDINGS of NOCICEPTIVE NEURONS.	2.08	1	0
Wounds, Stab Penetrating wounds caused by a pointed object.	2.08	1	0
Injuries, Neck [description not available]	2.08	1	0
Apoplexy [description not available]	2.49	2	0
Cerebral Ischemia [description not available]	2.49	2	0
Brain Ischemia Localized reduction of blood flow to brain tissue due to arterial obstruction or systemic hypoperfusion. This frequently occurs in conjunction with brain hypoxia (HYPOXIA, BRAIN). Prolonged ischemia is associated with BRAIN INFARCTION.	2.49	2	0
Stroke A group of pathological conditions characterized by sudden, non-convulsive loss of neurological function due to BRAIN ISCHEMIA or INTRACRANIAL HEMORRHAGES. Stroke is classified by the type of tissue NECROSIS, such as the anatomic location, vasculature involved, etiology, age of the affected individual, and hemorrhagic vs. non-hemorrhagic nature. (From Adams et al., Principles of Neurology, 6th ed, pp777-810)	2.49	2	0
Sensitivity and Specificity Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)	3.33	6	0
Anochlesia [description not available]	2.79	3	0
Abnormal Deep Tendon Reflex [description not available]	2.52	2	0
Reflex, Abnormal An abnormal response to a stimulus applied to the sensory components of the nervous system. This may take the form of increased, decreased, or absent reflexes.	2.52	2	0
Cardiac Diseases [description not available]	2.13	1	0
Cardiovascular Stroke [description not available]	2.13	1	0
Blood Clot [description not available]	2.13	1	0
Heart Diseases Pathological conditions involving the HEART including its structural and functional abnormalities.	2.13	1	0
Myocardial Infarction NECROSIS of the MYOCARDIUM caused by an obstruction of the blood supply to the heart (CORONARY CIRCULATION).	2.13	1	0
Thrombosis Formation and development of a thrombus or blood clot in the blood vessel.	2.13	1	0
Aggression Behavior which may be manifested by destructive and attacking action which is verbal or physical, by covert attitudes of hostility or by obstructionism.	2.13	1	0
Behavior Disorders [description not available]	3.06	1	0
Mental Disorders Psychiatric illness or diseases manifested by breakdowns in the adaptational process expressed primarily as abnormalities of thought, feeling, and behavior producing either distress or impairment of function.	3.06	1	0
Blood Pressure, High [description not available]	2.05	1	0
Hypokalemia Abnormally low potassium concentration in the blood. It may result from potassium loss by renal secretion or by the gastrointestinal route, as by vomiting or diarrhea. It may be manifested clinically by neuromuscular disorders ranging from weakness to paralysis, by electrocardiographic abnormalities (depression of the T wave and elevation of the U wave), by renal disease, and by gastrointestinal disorders. (Dorland, 27th ed)	2.05	1	0
Agitation, Psychomotor [description not available]	2.05	1	0
Hypertension Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more.	2.05	1	0
Psychomotor Agitation A feeling of restlessness associated with increased motor activity. This may occur as a manifestation of nervous system drug toxicity or other conditions.	2.05	1	0
Psychoses, Drug [description not available]	2.46	2	0
Tachycardia, Supraventricular A generic expression for any tachycardia that originates above the BUNDLE OF HIS.	2.47	2	0
Bilateral Headache [description not available]	2.07	1	0
Hemorrhage, Subarachnoid [description not available]	2.07	1	0
Headache The symptom of PAIN in the cranial region. It may be an isolated benign occurrence or manifestation of a wide variety of HEADACHE DISORDERS.	2.07	1	0
Subarachnoid Hemorrhage Bleeding into the intracranial or spinal SUBARACHNOID SPACE, most resulting from INTRACRANIAL ANEURYSM rupture. It can occur after traumatic injuries (SUBARACHNOID HEMORRHAGE, TRAUMATIC). Clinical features include HEADACHE; NAUSEA; VOMITING, nuchal rigidity, variable neurological deficits and reduced mental status.	2.07	1	0
Acidosis, Respiratory Respiratory retention of carbon dioxide. It may be chronic or acute.	2.07	1	0
Convulsions, Grand Mal [description not available]	2.07	1	0
Epilepsy, Tonic-Clonic A generalized seizure disorder characterized by recurrent major motor seizures. The initial brief tonic phase is marked by trunk flexion followed by diffuse extension of the trunk and extremities. The clonic phase features rhythmic flexor contractions of the trunk and limbs, pupillary dilation, elevations of blood pressure and pulse, urinary incontinence, and tongue biting. This is followed by a profound state of depressed consciousness (post-ictal state) which gradually improves over minutes to hours. The disorder may be cryptogenic, familial, or symptomatic (caused by an identified disease process). (From Adams et al., Principles of Neurology, 6th ed, p329)	2.07	1	0
Delayed Effects, Prenatal Exposure [description not available]	2.08	1	0
Anxiety Feelings or emotions of dread, apprehension, and impending disaster but not disabling as with ANXIETY DISORDERS.	2.08	1	0

jwh 018

Description

Cross-References

Synonyms (43)

Research Excerpts

Toxicity

Pharmacokinetics

Compound-Compound Interactions

Bioavailability

Dosage Studied

Drug Classes (1)

Protein Targets (8)

Potency Measurements

Inhibition Measurements

Activation Measurements

Biological Processes (83)

Molecular Functions (21)

Ceullar Components (32)

Bioassays (78)

Research

Studies (156)

Market Indicators

Research Demand Index: 56.70

Study Types

jwh 018

Description

Cross-References

Synonyms (43)

Research Excerpts

Toxicity

Pharmacokinetics

Compound-Compound Interactions

Bioavailability

Dosage Studied

Drug Classes (1)

Protein Targets (8)

Potency Measurements

Inhibition Measurements

Activation Measurements

Biological Processes (83)

Molecular Functions (21)

Ceullar Components (32)

Bioassays (78)

Research

Studies (156)

Market Indicators

Research Demand Index: 56.70

Study Types

Related Drugs (100)

Related Conditions (62)